Tübingen, Germany, January 26, 2022 Acousia Therapeutics GmbH – together with its companions from the Translational Listening to Analysis Team on the Tübingen Listening to Analysis Heart (Division of Otolaryngology, Head and Neck Surgical procedure, College of Tübingen) and Synovo GmbH (Tübingen) – will probably be presenting knowledge at the Synovia corporate’s scientific degree lead candidate ACOU085 on the forty fifth Annual MidWinter Assembly of the Affiliation for Analysis in Otolaryngology to be held nearly on February 5–9, 2022.
ACOU085 is a proprietary small molecule, otoprotective drug candidate. In December 2021, it was once granted a CTA for initiation of first-in-human Section 1b scientific trial via the German BfArM. The ACOU085 poster shows on the 2022 ARO MidWinter Assembly will duvet preclinical pharmacology, pharmacokinetic and native publicity knowledge bought the usage of a proprietary, sustained-release formula for transtympanic management.
Small-Molecule KCNQ4 Agonist Protects In opposition to Outer Hair Mobile Loss within the SAMP8 Mouse Fashion of Age-Similar Listening to Loss (Peixoto Pinheiro et al.)
This proof-of-concept learn about makes use of the senescence-accelerated mouse inclined 8 (SAMP8) fashion to reveal the facility of repeated ACOU085 administrations to seriously scale back age-related ABR threshold shifts. This was once supported via a histological demonstration of decreased OHC loss on this age-related listening to loss (ARHL) fashion the usage of the radical KCNQ4 agonist ACOU085.
Translational Building of ACOU085 for the Prevention of Cisplatin-Brought on Listening to Loss (CIHL) (Dyhrfjeld-Johnsen et al.)
This pharmacokinetic and native publicity learn about, compares the transtympanic management of proprietary sustained-release formulations of ACOU085 in SAMP8 mice and guinea pigs with fastened drug load and management quantity relative to the species-specific interior ear quantity. Important interior ear publicity is accomplished in each species, with an extended length of publicity within the better species receiving the most important absolute quantity of the proprietary formula.
About Acousia Therapeutics GmbH
Privately-held Acousia Therapeutics GmbH is primarily based in Tübingen, Germany. The corporate is devoted to the identity and building of small molecules for efficient prevention and remedy of various etiologies of listening to loss. Acousia develops medicine for native and systemic packages.
Touch
Tim Boelke, M.D.
boelke@acousia.com
